期刊论文详细信息
BMC Cancer
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis
Susanne Fuessel7  Kati Erdmann7  Helge Taubert5  Andrea Lohse-Fischer7  Stefan Zastrow7  Matthias Meinhardt2  Karen Bluemke6  Lorenz Hofbauer4  Paolo Fornara3  Bernd Wullich5  Gustavo Baretton2  Viktor Magdolen1  Manfred P Wirth7  Matthias Kotzsch2 
[1] Clinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München, Ismaninger Strasse 22, 81675 München, Germany
[2] Institute of Pathology, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
[3] Department of Urology, Martin Luther Universität Halle-Wittenberg, Ernst-Grube-Strasse 40, 06120 Halle, Germany
[4] Department of Medicine III, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
[5] Department of Urology, Universität Erlangen, Hartmannstrasse 14, 91054 Erlangen, Germany
[6] Institute of Legal Medicine, Martin Luther Universität Halle-Wittenberg, Franzosenweg 1, 06112 Halle, Germany
[7] Department of Urology, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
关键词: uPA system;    uPAR;    uPA;    Renal cell carcinoma;    Prognostic biomarker;    PAI-1;   
Others  :  1117854
DOI  :  10.1186/1471-2407-14-974
 received in 2014-02-18, accepted in 2014-12-11,  发布年份 2014
PDF
【 摘 要 】

Background

Members of the urokinase-type plasminogen activator (uPA) system including uPA, its receptor uPAR and the plasminogen activator inhibitor 1 (PAI-1) play an important role in tumour invasion and progression in a variety of tumour types. Since the majority of clear cell renal cell carcinoma (ccRCC) shows distant metastasis at time of diagnosis or later, the interplay of uPA, uPAR and PAI-1 might be of importance in this process determining the patients’ outcome.

Methods

Corresponding pairs of malignant and non-malignant renal tissue specimens were obtained from 112 ccRCC patients without distant metastasis who underwent tumour nephrectomy. Tissue extracts prepared from fresh-frozen tissue samples by detergent extraction were used for the determination of antigen levels of uPA, uPAR and PAI-1 by ELISA. Antigen levels were normalised to protein concentrations and expressed as ng per mg of total protein.

Results

Antigen levels of uPA, uPAR, and PAI-1 correlated with each other in the malignant tissue specimens (rs=0.51-0.65; all P<0.001). Antigen levels of uPA system components were significantly higher in tissue extracts of non-organ confined tumours (pT3+4) compared to organ-confined tumours (pT1+2; all P<0.05). Significantly elevated levels of uPAR and PAI-1 were also observed in high grade ccRCC. When using median antigen levels as cut-off points, all three uPA system factors were significant predictors for disease-specific survival (DSS) in univariate Cox’s regression analyses. High levels of uPA and uPAR remained independent predictors for DSS with HR=2.86 (95% CI 1.07-7.67, P=0.037) and HR=4.70 (95% CI 1.51-14.6, P=0.008), respectively, in multivariate Cox’s regression analyses. A combination of high antigen levels of uPA and/or uPAR further improved the prediction of DSS in multivariate analysis (HR=14.5, 95% CI 1.88-111.1, P=0.010). Moreover, high uPA and/or uPAR levels defined a patient subgroup of high risk for tumour-related death in ccRCC patients with organ-confined disease (pT1+2) (HR=9.83, 95% CI 1.21-79.6, P=0.032).

Conclusions

High levels of uPA and uPAR in tumour tissue extracts are associated with a significantly shorter DSS of ccRCC patients without distant metastases.

【 授权许可】

   
2014 Fuessel et al.; licensee BioMed Central.

【 预 览 】
附件列表
Files Size Format View
20150206011042595.pdf 353KB PDF download
Figure 2. 100KB Image download
Figure 1. 72KB Image download
【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】
  • [1]Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011, 60(4):615-621.
  • [2]Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012, 62(4):220-241.
  • [3]Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS: Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol 2007, 9(2):47-56.
  • [4]Buchner A, Riesenberg R, Kotter I, Hofstetter A, Stief C, Oberneder R: Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma. Cancer 2006, 106(7):1514-1520.
  • [5]Di Lorenzo G, Autorino R, Sternberg CN: Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009, 56(6):959-971.
  • [6]Pinto A: Adjuvant therapy for renal cell carcinoma. Clin Genitourin Cancer 2014, 12:408-412.
  • [7]Eichelberg C, Junker K, Ljungberg B, Moch H: Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 2009, 55(4):851-863.
  • [8]Finley DS, Pantuck AJ, Belldegrun AS: Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl 2):4-13.
  • [9]Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI: Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol 2011, 60(4):644-661.
  • [10]McMahon B, Kwaan HC: The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008, 36(3–4):184-194.
  • [11]Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brunner N, Foekens J, Harbeck N, Schmitt M: Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10(7):947-962.
  • [12]Mondino A, Blasi F: uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004, 25(8):450-455.
  • [13]Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol 2008, 214(3):283-293.
  • [14]Smith HW, Marshall CJ: Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010, 11(1):23-36.
  • [15]Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008, 34(2):122-136.
  • [16]Schmitt M, Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brunner N, Foekens J, Harbeck N: Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10(8):1051-1067.
  • [17]de Bock CE, Wang Y: Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004, 24(1):13-39.
  • [18]Hoyer-Hansen G, Lund IK: Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007, 44:65-102.
  • [19]Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H: Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 2005, 174(2):461-465.
  • [20]Choi JW, Lee JH, Park HS, Kim YS: PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma. J Clin Pathol 2011, 64(10):893-897.
  • [21]Zubac DP, Wentzel-Larsen T, Seidal T, Bostad L: Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 2010, 10:20. BioMed Central Full Text
  • [22]Chautard D, Dalifard I, Chassevent A, Guyetant S, Daver A, Vielle B, Soret JY: Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urology 2004, 63(6):1055-1060.
  • [23]Swiercz R, Wolfe JD, Zaher A, Jankun J: Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res 1998, 4(4):869-877.
  • [24]Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K: Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996, 78(3):487-492.
  • [25]Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F: Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urol 1996, 155(3):858-862.
  • [26]Veeratterapillay R, Simren R, El-Sherif A, Johnson MI, Soomro N, Heer R: Accuracy of the revised 2010 TNM classification in predicting the prognosis of patients treated for renal cell cancer in the north east of England. J Clin Pathol 2012, 65(4):367-371.
  • [27]Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6(7):655-663.
  • [28]Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994, 54(10):2527-2530.
  • [29]Luther T, Flossel C, Albrecht S, Kotzsch M, Muller M: Tissue factor expression in normal and abnormal mammary gland. Nat Med 1996, 2(5):491-492.
  • [30]Bouchet-Bernet C, Spyratos F, Andrieu C, Deytieux S, Becette V, Oglobine J: Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res Treat 1996, 41(2):141-146.
  • [31]Sweep CG, Geurts-Moespot J, Grebenschikov N, de Witte JH, Heuvel JJ, Schmitt M, Duffy MJ, Janicke F, Kramer MD, Foekens JA, Brunner N, Brugal G, Pedersen AN, Benraad TJ: External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 1998, 78(11):1434-1441.
  • [32]Span PN, Witjes JA, Grebenchtchikov N, Geurts-Moespot A, Moonen PM, Aalders TW, Vriesema JL, Kiemeney LA, Schalken JA, Sweep FC: Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int 2008, 102(2):177-182.
  • [33]Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V: Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA. Int J Mol Med 2008, 21(2):251-259.
  • [34]Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG: The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000, 60(3):636-643.
  • [35]Taubert H, Wurl P, Greither T, Kappler M, Bache M, Lautenschlager C, Fussel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br J Cancer 2010, 102(4):731-737.
  • [36]Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N: Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004, 24(6):4147-4161.
  • [37]de Witte H, Pappot H, Brunner N, Grondahl-Hansen J, Hoyer-Hansen G, Behrendt N, Guldhammer-Skov B, Sweep F, Benraad T, Dano K: ELISA for complexes between urokinase-type plasminogen activator and its receptor in lung cancer tissue extracts. Int J Cancer 1997, 72(3):416-423.
  • [38]Harbeck N, Thomssen C: A new look at node-negative breast cancer. Oncologist 2011, 16(Suppl 1):51-60.
  文献评价指标  
  下载次数:62次 浏览次数:11次